Get the Stockscreener App
2.00
1.52%
0.03
After Hours:
1.98
-0.02
-1.00%
Palisade Bio Inc stock is traded at $2.00, with a volume of 1.84M.
It is up +1.52% in the last 24 hours and up +3.63% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.97
Open:
$1.98
24h Volume:
1.84M
Relative Volume:
0.48
Market Cap:
$335.25M
Revenue:
$250.00K
Net Income/Loss:
$-16.78M
P/E Ratio:
-1.347
EPS:
-1.4848
Net Cash Flow:
$-10.85M
1W Performance:
+3.63%
1M Performance:
+3.63%
6M Performance:
+20.48%
1Y Performance:
+139.58%
1-Day Range:
$1.90
$2.00
1-Week Range:
$1.90
$2.215
52-Week Range:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.00 | 330.22M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio (PALI) price target decreased by 12.09% to 10.20 - MSN
Palisade Bio Data Supports Once-Daily Ulcerative Colitis Treatment Due to Sustained IC90 Coverage - geneonline.com
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug By Investing.com - Investing.com South Africa
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug - Investing.com
Palisade UC pill stayed above IC90 through the dosing interval - Stock Titan
Palisade Bio Reports Additional Phase 1a/b Data - GlobeNewswire
MSN Money - MSN
Major share increase and equity plan votes ahead for Palisade Bio (NASDAQ: PALI) - Stock Titan
Palisade Bio Participates in Virtual Investor "What This Means" Segment - 富途牛牛
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN
PALI Should I Buy - Intellectia AI
PALI Palisade Bio posts narrower than expected Q4 2025 loss, shares gain more than four percent.Secondary Offering - Cổng thông tin điện tử tỉnh Lào Cai
Analysts Offer Predictions for Palisade Bio Q1 Earnings - MarketBeat
Brokers Issue Forecasts for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (NASDAQ: PALI) asks shareholders to lift authorized shares to 450M - Stock Titan
Palisade Bio Develops Crohn’s Disease Treatment Following Positive Study - HarianBasis.co
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Insider Monkey
Palisade Bio to present ulcerative colitis data at DDW conference By Investing.com - Investing.com India
Palisade Bio to present ulcerative colitis data at DDW conference - Investing.com
Palisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative Colitis - Quiver Quantitative
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 - GlobeNewswire
5 Best Biotech Stocks Under $10 to Buy - Insider Monkey
Piper Sandler reiterates Overweight rating on Palisade Bio stock By Investing.com - Investing.com South Africa
Piper Sandler reiterates Overweight rating on Palisade Bio stock - Investing.com
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy - MarketBeat
Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI) - MarketBeat
Palisade Bio CEO, CMO to give virtual Needham presentation April 16 - Stock Titan
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - The Manila Times
Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN
Is Palisade Bio (PALI) Stock a future winner | Price at $1.94, Up 1.31%Trending Social Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Earnings Miss: Can Palisade Bio Inc expand its profit margins2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Palisade Bio partners with Iterative Health to advance PALI-2108 - TipRanks
Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - Investing.com Australia
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):